Page 1

altimmune Altimmune Announces Positive Interim Data from ALT - 801 Phase 1 Trial in Overweight and Obese Volunteers June 16 , 2021 • Weight loss of 5.4 % achieved at 6 weeks of treatment with 1.8 mg once weekly dose , surpassing the 2 % pre - established treatment target • Ascending multi - dose regimen well - tolerated without necessity for dose titration • Trial continuing with 12 - week data expected in Q3 2021 . Company plans to file an additional IND and initiate an obesity program in 2021 • Altimmune to host a conference call today at 8:30 a.m. ET GAITHERSBURG , Md . , June 16 , 2021 ( GLOBE NEWSWIRE ) -- Altimmune , Inc. ( Nasdaq : ALT ) , a clinical - stage biopharmaceutical company , today announced results from a prespecified 6 - week interim analysis of its ongoing 12 - week , Phase 1 , placebo - controlled , single and multiple ascending dose trial of ALT - 801 , an investigational GLP - 1 / glucagon dual receptor agonist , in healthy overweight and obese volunteers . The study is currently being conducted in Australia under a clinical trial application . The interim data showed a mean weight loss of 5.4 % was achieved by Week 6 with a once weekly ALT - 801 dose of 1.8 mg administered subcutaneously ( sc ) compared to a weight gain of 0.9 % in the placebo group ( net change from placebo of 6.3 % , p < .0001 ) , surpassing the pre - established treatment target of 2 % weight loss . All but one subject who received the 1.8 mg sc dose achieved at least 3 % weight loss by Week 6 . A lower dose cohort that received a weekly 1.2 mg sc dose achieved a mean weight loss of 1.8 % ( net change from placebo of 2.7 % , p < .05 ) at the same time point . ALT - 801 was well - tolerated without dose titration , with transient nausea rates of 14.3 % at the 1.2 mg dose and 22.2 % at the 1.8 mg dose , and no reports of vomiting , diarrhea or constipation at either dose . All nausea events at the 1.8 mg dose were mild in severity . Gastrointestinal adverse events have required other GLP - 1 based agents to dose titrate over 16 to 20 weeks to maintain adequate tolerability . " These data are encouraging considering that only a 2 % weight loss was targeted at 6 weeks of treatment and that nausea rates were low , without emesis , which is particularly notable in the absence of dose titration , " commented Stephen Harrison , MD , Visiting Professor of Hepatology , University of Oxford , and Medical Director , Pinnacle Research . " The high degree of weight loss , the very good safety and tolerability profile , and the absence of dose titration with short treatment duration is very favorable for ALT - 801 and makes it an attractive candidate among the GLP - 1 class of drugs . Based on the relationship between weight loss and liver fat reduction , and NASH resolution observed in other studies , ALT - 801 appears to be a promising therapeutic candidate for both obesity and NASH . " Because the recruited study population was young ( mean age 29.8 years ) and non - diabetic , the proportion of subjects with MRI - PDFF greater than 10 % was insufficient to perform an analysis of liver fat reduction in this population . Consequently , the Company plans to expand the enrollment criteria and conduct a separate 12 - week Phase 1b study of diabetic and non - diabetic subjects with non - alcoholic fatty liver disease ( NAFLD ) in the United States , which is anticipated to commence in Q3 2021 , and to initiate a 52 - week biopsy - driven NASH trial in Q1 2022. The expansion of enrollment criteria to diabetic and older subjects will accelerate the recruitment of the target NAFLD population and mirror the anticipated study population in the 52 - week trial . The ALT - 801 Phase 1 trial is currently progressing through higher dose cohorts , and the Company plans to report the results following 12 - weeks of dosing in Q3 2021. Based on these latest results , Altimmune now plans to file a second IND in obesity in Q3 2021 to supplement its ongoing NASH program . " We are very excited about the potential for ALT - 801 in the expanding GLP - 1 therapeutics marketplace , " said Vipin K. Garg , Ph.D. , President and Chief Executive Officer of Altimmune . " We know that weight loss is strongly correlated with NASH resolution and that the obesity epidemic in developed nations has led to an unacceptable increase in chronic illnesses . Assuming ALT - 801 is shown to improve upon the metabolic control and side effect profile of existing GLP - 1 therapies , we believe that ALT - 801 could enable more patients to benefit from this type of treatment . " About the ALT - 801 Phase 1 Trial The ALT - 801 Phase 1 clinical trial is a placebo - controlled , first - in - human , single ascending dose ( SAD ) and multiple ascending dose ( MAD ) study in overweight and obese volunteers being conducted in Australia under a clinical trial application . Study subjects did not participate in behavioral weight loss programs or undergo caloric restriction . The primary objectives of the trial are to assess the safety and tolerability , pharmacokinetics , and weight loss in ALT - 801 recipients compared to placebo over 12 weeks of weekly dosing . Reduction in liver fat content will be assessed in a separate 12 - week Phase 1b trial of diabetic and non - diabetic subjects with NAFLD anticipated to commence in Q3 2021. Dosing in the MAD phase commenced with a cohort receiving ALT - 801 1.2 mg sc or placebo once weekly and is progressing through higher dose cohorts . Subjects in the 1.2 mg and 1.8 mg cohorts currently have completed 6 weeks of treatment . Interim analyses at 6 weeks of dosing have been performed for the first two study cohorts , and the results of 12 weeks of dosing in these and additional cohorts are expected to be announced in Q3 2021 . Conference Call Information Date : Time : Domestic Dial - in : International Dial - in : Conference ID : Wednesday , June 16 , 2021 8:30 am Eastern Time 877-423-9813 201-689-8573 13720570